Ipca Laboratories (NSE:IPCALAB) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:IPCALAB Ipca Laboratories Ltd NSE:IPCALAB
93 GF Score
Price ₹1,823.30
GF Value ₹1,603.76
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ipca Laboratories Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

NSE:IPCALAB
93GF Score
Ipca Laboratories Ltd NSE:IPCALAB
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued. The current stock price of ₹1,823.30 is trading 13.7% above its estimated GF Value™ of ₹1,603.76. GuruFocus considers Ipca Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:IPCALAB:

  • Dividends Received:
  • GF Value™: ₹1,603.76 vs. price of ₹1,823.30 (13.7% above fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ipca Laboratories Business Description

Other Exchanges 524494:India
Address No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
93GF Score

Get the complete analysis for NSE:IPCALAB

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,823.30
Price
₹1,603.76
GF Value